Skip to content
10-Q

Quarterly Report

Aligos Therapeutics, Inc. ALGS

0000950170-24-122371

← back to feed
Filed
Nov 6, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Short Term Investments Q3 2024 · Sep 30, 2024 $39.59M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $35.33M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $135.7M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $70.43M
Current Liabilities Q3 2024 · Sep 30, 2024 $20.96M
Current Liabilities Q3 2024 · Dec 31, 2023 $23.91M
Total Liabilities Q3 2024 · Sep 30, 2024 $38.33M
Total Liabilities Q3 2024 · Dec 31, 2023 $59.45M
Current Assets Q3 2024 · Sep 30, 2024 $79.82M
Current Assets Q3 2024 · Dec 31, 2023 $141.08M
Total Assets Q3 2024 · Sep 30, 2024 $88.43M
Total Assets Q3 2024 · Dec 31, 2023 $151.53M
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.74M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.73M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$56.34M
Stockholders Equity Q3 2024 · Sep 30, 2023 $54.82M
Stockholders Equity Q3 2024 · Jun 30, 2023 $69.64M
Stockholders Equity Q3 2024 · Dec 31, 2022 $103.9M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$10.37
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$34.59
Eps Basic restated Q3 2024 · Sep 30, 2023 −$10.37
Eps Basic restated Q3 2024 · Sep 30, 2023 −$34.59
Sga Expense Q3 2024 · Sep 30, 2023 $6.44M
Sga Expense Q3 2024 · Sep 30, 2023 $24.2M
Rd Expense Q3 2024 · Sep 30, 2023 $15.87M
Rd Expense Q3 2024 · Sep 30, 2023 $50.78M
Net Income Q3 2024 · Sep 30, 2023 −$18.04M
Net Income Q3 2024 · Sep 30, 2023 −$59.79M
Operating Income Q3 2024 · Sep 30, 2023 −$19.07M
Operating Income Q3 2024 · Sep 30, 2023 −$62.13M
Revenue Q3 2024 · Sep 30, 2023 $1.09M
Revenue Q3 2024 · Sep 30, 2023 $5.52M